Clinical and Experimental Gastroenterology

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advancements in pharmacological, surgical and adjunct therapeutic modalities for inflammatory bowel disease", organized by Guest Advisor Dr Syed Hassan in Clinical and Experimental Gastroenterology.

Advancements in experimental platforms have enhanced our understanding of disease-pertinent pathophysiology for inflammatory bowel diseases (IBD). This has fueled identification of novel molecular targets, thus revolutionizing treatment aspirations from symptomatic control to well-defined objective aspirations by implementation of the treat-to-target approach. Despite these rapid advances, a significant subset of patients (40%) fail to respond to therapy. A further 30% of patients in remission lose response, necessitating the need for cycling through numerous therapeutic options. Subsequently, this increases the risk of adverse events and imposes a significant financial burden. More importantly, long term unabated inflammation also increases the risk of disease-associated long-term complications including strictures, fistulas, perforations and colorectal cancer. The rapid introduction of novel agents into treatment algorithms coupled with lack of comparative data has complicated the management of IBD. While landmark clinical trials have delineated the efficacy and safety of novel biologics and small molecules, a collective analysis of data reveals a perceived therapeutic ceiling due to a plateau in the attainment of disease remission. The clinical and symptomatic heterogeneity of IBD is known to complicate patient management. This is attributed to varying disease location, disease behavior, age at disease onset, treatment status, presence of perianal disease and extra-intestinal manifestations. Modern transcriptomics have established the notion of heterogeneity in IBD pathogenic responses based on disease characteristics. Together this indicates a critical unmet need in the management of IBD. 

This Article Collection will aim to highlight cutting edge clinical research to optimize therapeutic and alternative adjunct modalities to improve clinical outcomes and quality of life for IBD patients. We encourage original research that focuses on the following:

• Comparing efficacy and safety in a variety of clinical situations to aid decision making in the therapeutic ladder.
• Comparing short-term and long-term outcomes associated with monotherapy and advanced combination therapy.
• Real world studies in refractory IBD cohorts.
• Ascertaining therapeutic outcomes and safety in the inpatient management of IBD.
• Studies informing therapeutic de-escalation strategies.
• Inform treatment strategies for patients with limited proctitis, ostomies, J-pouch and small bowel disease.
• Studies aiding surgical treatment selection with a focus on positioning of surgical therapy.
• Illustrating outcomes and safety associated with newer surgical techniques.
• Identifying optimal timing for surgery.
• Evaluating the role of dietary therapy as an adjunct measure for IBD.
• Assessing the impact of nutritional status on overall outcomes.
• Role of physical and psychological factors and disease flares to improve holistic treatment of IBD patients.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 30 June 2025.

Please submit your manuscript on our website, quoting the promo code SZAGF for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection. 

Guest advisor

Dr. Syed Adeel Hassan, University of Kentucky, USA

[email protected]

View all papers in this article collection